Key statistics
On Friday, Lyell Immunopharma Inc (LYEL:NSQ) closed at 9.24, 20.78% above the 52 week low of 7.65 set on Jun 02, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.62 |
---|---|
High | 9.75 |
Low | 9.24 |
Bid | 9.40 |
Offer | 10.02 |
Previous close | 9.52 |
Average volume | 38.30k |
---|---|
Shares outstanding | 15.43m |
Free float | 11.31m |
P/E (TTM) | -- |
Market cap | 146.92m USD |
EPS (TTM) | -24.32 USD |
Data delayed at least 15 minutes, as of Jul 18 2025 21:00 BST.
More ▼
- Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
- Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
- Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
- Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
- Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025
- Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025
- Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
- Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
- Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
More ▼